Ikris Pharma Network, headquartered in the India is interested in obtaining authorization from Pharmaceutical companies to manage distribution through named patient supplies exclusively in India, other SAARC counties or and in emerging markets of Asia, particularly in the following areas:-
- Rare and orphan diseases
The area of business that we cover, is unique in a sense that it requires a deep understanding of the regulatory and geographical outreach challenges. Regulation can have wide variation from country to country. What may be applicable in EU may not work that way in India.
IPN brings the experience and domain knowledge required to work in partnership with Institutions and governments to ensure patients can benefit from those innovative medicines.
If you are a manufacturer looking to distribute your newly approved medicines to be distributed under Named Patient Program, then please contact our Business Development Team, who will be happy to provide you with any information you require about working with IkisPharmaNetwork.